Indeed, preventive rather than therapeutic treatment with Syk inhibitor limited AAA formation to the same degree as γ‐chain deficiency, and reduced inflammation, oxidative response, and phenotype switching in VSMC and macrophages. This evidence concerns the gene SYK and triple-A syndrome.